IUC26589-95 First-Line or Maintenance Immune Checkpoint Inhibitors in Older Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
Abstract Background Evidence on immune-based treatment in older patients with advanced urothelial carcinoma are limited because age-specific outcomes are usually exploratory. We assessed the efficacy of first-line and maintenance immune-based strategies in patients aged ≥65 years. Methods PubMed/MEDLINE, Embase, Cochra...